Company: PMVP
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030414
Chunk: 191

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 191
---
,849

        $
        6,748

        $
        6,649

        Stock-based compensation

        5,216

        6,857

        6,729

        External

        15,856

        10,642

        11,674

        Total general and administrative

        26,921

        24,247

        25,052

        Loss from Operations
         
        $
        85,448

        $
        80,132

        $
        77,040

14. Subsequent EventsThe State of New Jersey’s Technology Business Tax Certificate Program allows certain high technology and biotechnology companies to sell NOL carryforwards and R&D tax credits to other New Jersey-based corporate taxpayers. The Company has applied for and received preliminary confirmation for its sale of NOLs related to the tax years ended December 31, 2021 to 2023 in the amount of approximately $2,196, which the Company expects to recognize in the second quarter of 2025, upon receipt of the certificates for the refund. Subsequent to December 31, 2024, the Company received $1,415 of cash for the NOL tax credit sales.

 124

Item 9.    Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

None. 

Item 9A.    Controls and Procedures. 

Evaluation of Disclosure Controls and Procedures

Our management maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

As of December 31, 2024, the Company conducted an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15(d)-15(e) promulgated under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of the end of